EGFR and non-small cell lung carcinoma: Moreover, studies have elucidated that among individuals diagnosed with early or locally advanced NSCLC, the ones with an epidermal growth factor receptor (EGFR) mutated disease are more likely to relapse after post-operative chemotherapy or other definitive interventions, compared with the EGFR wildtype counterpart (Takahashi et al., 2022).